Holen Sie sich die Stockscreener-App
3.70
2.12%
-0.08
Schlusskurs vom Vortag:
$3.78
Offen:
$3.78
24-Stunden-Volumen:
275.46K
Relative Volume:
0.68
Marktkapitalisierung:
$222.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-197.68M
KGV:
-0.984
EPS:
-3.76
Netto-Cashflow:
$-158.88M
1W Leistung:
+2.21%
1M Leistung:
+3.35%
6M Leistung:
-62.93%
1J Leistung:
+52.26%
1-Tages-Spanne:
$3.65
$3.805
1-Wochen-Bereich:
$3.51
$3.91
52-Wochen-Spanne:
$1.92
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1200 PAGE MILL RD, PALO ALTO, CA
Vergleichen Sie KOD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
3.70 | 222.66M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion - The Globe and Mail
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? - Yahoo Finance
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Kodiak Sciences Q2 EPS Forecast Decreased by Zacks Research - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Position Increased by Public Employees Retirement System of Ohio - Defense World
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Kodiak Sciences Holds 2025 Annual Stockholders Meeting - TipRanks
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare C - GuruFocus
Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize
Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus
Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus
Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan
Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World
MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter
MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
JPMorgan Chase & Co. Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):